A sub 100 million market cap company teams up wit MIT in a Co-Development...
Regarding VX-864, its experimental treatment for the rare, inherited lung disease called alpha-1 antitrypsin deficiency, Vertex said a readout of a Phase 2 study is expected in the first half of the year. Last October, Vertex was forced to shelve its first drug for alpha-1 antitrypsin deficiency due to liver toxicity. Independent study monitors are taking regular looks at the safety data from the ongoing VX-864 study, and to date, patient enrollment continues, Vertex said Monday.
Skeptics grow impatient awaiting Cel-Sci to release there Phase 3 data on Cancer drug...
No legitimate reason exists for Cel-Sci to be taking this long, even accounting for Covid. The simple truth is Cel-Sci is trying to bury Multikine’s negative results, as it did previously when independent monitors tried to shut the study down twice, or when the FDA halted the study citing an “unreasonable and significant risk of illness or injury to human subjects.”
Amgen’s KRAS Cancer Drug slumps while a much smaller player makes major headway in...
Although the company did a poor job answering questions last week — Why suddenly study a lower dose of sotorasib if the higher dose is fine? Did the FDA discover something bad in sotorasib’s safety profile during its review? — it insisted there was nothing wrong with the 960 mg dose of sotorasib. Amgen also said it was the FDA that proposed looking at the efficacy and safety of a lower dose as a “post-marketing requirement” — meaning, presumably, after the higher dose was already approved.
Five things to consider about referring patients for CAR-T cell therapy, who will be...
This program ensures the treatment centers and HCPs administering Kymriah are prepared to manage CRS and neurological toxicities. In follow up analyses of the JULIET clinical study, the Kymriah safety profile has remained consistent.1,3,4 The most common adverse reactions (incidence >20%) were CRS, infections-pathogen unspecified, diarrhea, nausea, pyrexia, fatigue, hypotension, edema, and headache.
iTeos Therapeutics debuts first data on TIGIT-targeting cancer immunotherapy, while Avalon Globocare shows 90...
iTeos presented the EOS-448 Phase 1 study results at the annual meeting of the American Association for Cancer Research on Saturday. The TIGIT class of immunotherapy drugs is drawing a lot of attention from academia, industry, and investors because of its potential to greatly expand the pool of patients who might benefit from so-called checkpoint inhibitors.
U.S. government has invested $6 billion in Moderna’s Covid-19 vaccine while Avalon GloboCare works...
In 2016, Moderna received $8 million with the potential for up to $125 million from the Biomedical Advanced Research and Development Authority, a component of the U.S. Department of Health and Human Services, to accelerate development of an mRNA vaccine for Zika. (The company is still working on that project.)What makes the bankrolling of Moderna’s Covid-19 vaccine so extraordinary, Foroohar said, was the scale, which “reflects how unusual the pandemic is and the fact that this is very literally a once-in-a-lifetime event.”
As demand for CAR-T sky rockets Gilead and Bristol-Myers Squibb spend hundreds of millions...
The following year, it was bought by Gilead NASDAQ: GILD and its immunotherapy subsidiary, Kite, for $567 million. Since then, Kite has begun recruiting for a clinical trial of its solid tumor CAR-T candidate, but it has not yet moved past Phase 1.
Novartis and the Gates Foundation launch a new and exciting gene therapy project while...
The three-year collaboration, announced Wednesday, has initial funding of $7.28 million.Current gene therapy approaches being developed for sickle cell disease are complex, enormously expensive, and bespoke, crafting treatments for individual patients one at a time. The collaboration aims to instead create an off-the-shelf treatment that bypasses many of the steps of current approaches, in which cells are removed and processed outside the body before being returned to patients.
Last Mile Ride Share answer for Healixa (OTC Pink: EMOR)?
A Virtual Care Platform Covering Diagnosis to Treatment without leaving your Home
The camera on your phone is more powerful than you know. The infrared aspect...
Cashing in on Coronavirus Stocks in Q2
With revenues up more than 60% compared to last fiscal year-to-date, Nightfood has their sleep-friendly ice cream in over 800 stores including major divisions of the largest supermarket chains in the country such as Kroger (NYSE: KR), H-E-B, Albertsons (NYSE: ACI).
Latest News
Epazz Holdings (OTC Pink: EPAZ) Partnerships with UAE and Saudi Arabia...
ZenaDrone working to Establish New Partnerships with UAE and Saudi Arabia Companies at the Dubai Air Show
See the full release at: https://emerginggrowth.com/profile/epaz/
CHICAGO, November 15,...
